Research Projects & Grants

  • Individual patient program (IPP) use of Trametinib and Dabrafenib for Multisystem Langerhands Cell Histiocytosis, Role: Investigator, (11/2019) Status: Completed

College/University

  • POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS), Role: Investigator, Duke University, (12/2024 - 12/2025) Status: Approved
  • University of Alabama at Birmingham: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19, Role: PI, University of Alabama at Birmingham, (06/2020) Status: Approved

Federal

  • COG-APEC14B1: project: EveryChild - a registry, eligibility screening, biology and outcome study, Role: Investigator, Children Oncology Group, (09/2024 - 09/2025) Status: Approved
  • COG A031102: a randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus Ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors, Role: Investigator, Children Oncology Group, (09/2024 - 09/2025) Status: Approved
  • COG AAML 1921 / ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, Role: Investigator, Children Oncology Group, (08/2024 - 08/2025) Status: Approved
  • COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones, Role: Investigator, Children Oncology Group, (07/2024 - 07/2025) Status: Approved
  • COG ACNS1422: A Phase 2 Study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients, Role: Investigator, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
  • TSLP and pediatric leukemia mechanisms and treatment, Role: Investigator, National Cancer Institute/NIH/DHHS, (06/2024 - 06/2025) Status: Approved
  • COG AALL1621: phase 2 study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in children and young adults with relapsed or refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), Role: Investigator, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
  • COG- AREN03B2 - renal tumors classification, biology and banking study, Role: Investigator, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
  • COG-ANBL00B1 Neuroblastoma biology studies Revised 11/30/2000, Role: Investigator, Children Oncology Group, (04/2024 - 04/2025) Status: Approved
  • COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS), Role: Investigator, Children Oncology Group, (04/2024 - 04/2025) Status: Approved
  • COG AEWS1221: Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab (AMG 479, NSC# 120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid, Role: Investigator, Children Oncology Group, (02/2025 - 02/2026) Status: Approved
  • Children's Oncology Group (COG)-AALL0932: Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy), Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG - ACNS0334: A phase III randomized trial for the treatment of newly diagnosed supratentorial PNET and high risk medulloblastoma in children < 36 months old with intensive induction chemotherapy with methotrexate followed by consolidation with stem cell rescue vs. the same therapy without methotrexate, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - AEWS1031: A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-AAML1031: A phase III randomized trial for patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for patients with high allelic ratio FLT3/ITD, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy), Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) AALL1331: Risk-stratified randomized phase III testing of blinatumomab (IND#117467, NSC#765986) in first relapse of childhood B-Lymphoblastic Leukemia (B-ALL), Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AHOD 1331: randomized phase III study of Brentuximab Vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin Lymphoma (cHL) in children and adolescents, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AGCT1531: A phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs. cisplatin for standard risk pediatric and adult patients with germ cell tumors, Role: Investigator, Children Oncology Group, (02/2025 - 02/2026) Status: Approved
  • COG: AALL0434 - Intensified methotrexate, nelarabine (compound 506U78; IND# 52611) and augmented BFM therapy for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-Cell Lymphoblastic Lymphoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-ACNS0332: A study evaluating the efficacy of carboplatin administered concomitantly with radiation and isotretinoin as a pro-apoptotic agent in other than average risk medulloblastoma/PNET patients, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - AALL0631: A Phase III study of risk directed therapy for infants with acute lymphoblastic leukemia (ALL): Randomization of highest risk infants to intensive chemotherapy +/- FLT3 inhibition (CEP-701, lestaurtinib; IND#76431; NSC#617807), Role: Investigator, Children Oncology Group, (02/2024 - 07/2024) Status: Completed
  • COG- AHOD0831: A non-randomized phase III study of response adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin's Lymphoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG - ANBL0032 - Phase III randomized study of Chimeric antibody 14.18 (Ch14.18) in high risk Neuroblastoma following Myeloablative Therapy and autologous stem cell rescue, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG: AREN0533 - Treatment of newly diagnosed higher risk favorable histology Wilms tumors, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - ALTE05N1: Umbrella long-term follow-up protocol, Role: Investigator, Children Oncology Group, (11/2024 - 11/2025) Status: Approved
  • Sickle Cell Family Planning: A Surveillance, Prevention, & Caring Pathway, Role: Investigator, Maternal and Child Health Bureau/Health Resources and Services Administration/DHHS, (10/2023) Status: Approved
  • COG AAML1531: Risk-stratified therapy for acute myeloid leukemia in Down Syndrome, Role: Investigator, Children Oncology Group, (10/2024 - 10/2025) Status: Approved
  • Maternal Health Research Collaborative for Minority-Serving Institutions, Role: Co-Investigator, Maternal and Child Health Bureau/Health Resources and Services Administration/DHHS, (09/2023 - 09/2025) Status: Awarded
  • COG AOST1421: A phase 2 study of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 (Dinutuximab, NSC #764038, IND #4308) in combination with sargramostim (GM-CSF) in patients with recurrent osteosarcoma, Role: Investigator, Children Oncology Group, (03/2023 - 03/2024) Status: Completed
  • COG – ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Sort Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age, Role: Investigator, Children Oncology Group, (03/2023 - 02/2024) Status: Completed
  • COG-ANBLOOP3 - A Phase II/III study of the use of intravenous gammaglobulin therapy for patients with neuroblastoma associated opsoclonus-myoclonus-ataxia syndrome, Role: Investigator, Children Oncology Group, (04/2022 - 04/2023) Status: Completed
  • COG: ARST 0531 - Randomized study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and ironotecan (VI) for patients with intermediate-risk rhabdomyosarcoma (RMS), Role: Investigator, Children Oncology Group, (04/2022 - 04/2023) Status: Completed
  • COG ACCL 1333 / BMS CV185-155: a phase III randomized, open label, multi-center study of the safety and efficacy of apixaban for thromboembolism prevention versus no systemic anticoagulant prophylaxis during induction chemotherapy in children with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase, Role: Investigator, Children Oncology Group, (10/2021 - 10/2022) Status: Completed
  • COG ADVL1722 / Eisai E7389-G000-223:A phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS), Role: Investigator, Children Oncology Group, (01/2021 - 01/2022) Status: Completed
  • COG AAML1321/Novartis CAMN107A2203: A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic phase (CP) or with Ph+ CML in CP or accelerated phase (AP) resistance or intolerant to either imatibib or dasatinib, Role: Investigator, Children Oncology Group, (02/2020 - 02/2021) Status: Completed

For Profit Organization

  • COG ADVL1822/ Daiichi Sankyo, Inc. AC220-A-U202: A Phase 1/2, Multicenter, Dose-Escalating study to evaluate the safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib administration in combination with re-induction chemotherapy, and as a single-agent continuation therapy, in pediatric relapsed/refractory AML subjects ages 1 month to <18 years (and Young adults ages up to 21 years) with FLT3-ITB mutations, Role: Investigator, Daiichi Sankyo Pharma Development, (06/2024 - 06/2025) Status: Approved
  • A multicenter, prospective, open-label, clinical study to assess the effect of using a new risk score approach to select the most appropriate prophylaxis regimen for reaching a favorable outcome, when hemophilia A patients switch from standard half-life products to damoctocog alfa pegol (Jivi), Role: PI, Bayer Pharmaceuticals, (09/2023 - 01/2025) Status: Completed
  • EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas, Role: Investigator, Oncoceutics, Inc., (10/2022 - 10/2023) Status: Completed
  • Jazz Pharmaceuticals JZP458-201 (COG AALL1931): An open-label, multicenter study of RC-P in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) following hypersensitivity to E. coli-derived asparaginases, Role: Investigator, Jazz Pharmaceuticals, (01/2022 - 01/2023) Status: Completed
  • Pfizer B0661037: A randomized, open-label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anti-coagulation for the treatment of a venous thromboembolic event, Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (11/2021 - 11/2022) Status: Completed

Foreign

  • Pediatric blood and marrow transplant consortium (PBMTC) and Canadian Institutes of Health Research (CIHR) - GVHD-1202: Predictive biomarkers for pediatric chronic graft-versus-host disease, Role: Investigator, Canadian Institutes of Health Research, (09/2024 - 09/2025) Status: Approved

Internal

  • A randomized controlled trial comparing daily oral iron administration to every alternate day iron administration in the treatment of iron deficiency anemia in pediatric patients, Role: Investigator, LLU Dept. of Pediatrics, (08/2024) Status: Approved
  • Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection: An Institutional Experience, Role: Investigator, LLU Dept. of Pediatrics, (03/2021) Status: Approved
  • CRM for adults with chronic illnesses outpatient program research study, Role: Investigator, LLU Dept. of Social Work, (07/2019) Status: Approved
  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2024 - 09/2025) Status: Approved

Non-Profit Organization

  • The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved
  • PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative, Role: Investigator, Pediatric Blood and Marrow Transplant Consortium, (06/2024 - 06/2025) Status: Approved
  • NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries., Role: Investigator, National Marrow Donor Program, (06/2024 - 06/2025) Status: Approved
  • Improving quality of life for persons with SCD through Resilience and Empowerment (SCD-RE) Program, Role: Investigator, Networking California for Sickle Cell Care, (04/2022) Status: Approved
  • National Marrow Donor Program® (NMDP) - 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved
  • Develop content for key deliverables related to SCD pediatric to adult care transition, Role: PD/PI, National Alliance of Sickle Cell Centers, (08/2024 - 07/2025) Status: Awarded

Other Research

  • Original project’s as Principal Investigator: LLeRA # Principal Investigator   Project Title PT 2180090   Jain, Akshat   (CDA) Bayer HealthCare Pharmaceuticals Inc. / Dr. Akshat Jain PT 2180091   Jain, Akshat   (CDA) Global Blood Therapeutics, Inc. / Dr. Akshat Jain PT 2190027   Jain, Akshat   (CDA) Sanofi / Dr. Akshat Jain PT 2190280   Jain, Akshat   ATLAS-PPX: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in patients with hemophilia A and B previously receiving factor or bypassing agent prophylaxis. PT 2190289   Jain, Akshat   (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain PT 2190387   Jain, Akshat   (CDA) Baxalta US, Inc. / Dr. Akshat Jain PT 2190571   Jain, Akshat   ATLAS-INH: A Phase 3 study to evaluate the efficacy and safety of fitsurian in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX PT 2200285   Jain, Akshat   National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 PT 2200406   Jain, Akshat   (CDA) Emory University / Dr. Akshat Jain PT 2200538   Jain, Akshat   (CDA) Dr. Akshat Jain / Octapharma PT 2200565   Jain, Akshat   (CDA) Trio Health / Dr. Akshat Jain PT 2210113   Jain, Akshat   Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Wellebrand Disease Patients Under the Age of 6 Years PT 2210227   Jain, Akshat   An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor) PT 2210231   Jain, Akshat   (CDA) Spark Therapeutics / Dr. Akshat Jain PT 2210258   Jain, Akshat   (CDA) Pfizer, Inc. / Dr. Akshat Jain PT 2210367   Jain, Akshat   ATHN Data Quality Controls / American Thrombosis and Hemostasis Network Affiliation Agreement PT 2220406   Jain, Akshat   (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain PREDICT Clinical Study PT 2220452   Jain, Akshat   (CDA) Sanofi US Services / Dr. Akshat Jain PT 2220467   Jain, Akshat   (CDA) Spark Therapeutics / Dr. Akshat Jain PT 2230034   Jain, Akshat   (CDA) CSL Behring, LLC / Dr. Akshat Jain PT 2230035   Jain, Akshat   (CDA) NASCC / Dr. Akshat Jain PT 2230052   Jain, Akshat   Gene and Gene-modified Cell Therapies Medical Education IRB 5200186   Jain, Akshat   University of Alabama at Birmingham: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 IRB 5210168   Jain, Akshat   Clinical study to investigate the efficacy, pharmacokinetics, immunogenicity and safety of Wilate in severe Von Willebrand disease patients under the age of 6 years         Oncology clinical trials and P.I./Co-P.I.   IRB 40303   Children’s Oncology Group   COG-ANBL00B1 Neuroblastoma biology studies Revised 11/30/2000 IRB 5100025   Children’s Oncology Group   COG - ACNS0334: A phase III randomized trial for the treatment of newly diagnosed supratentorial PNET and high risk medulloblastoma in children &lt 36 months old with intensive induction chemotherapy with methotrexate followed by consolidation with stem cell rescue vs. the same therapy without methotrexate IRB 5100187   Children’s Oncology Group   Children's Oncology Group (COG) - ALTE05N1: Umbrella long-term follow-up protocol IRB 5100217   Children’s Oncology Group   Children's Oncology Group (COG)-AALL0932: Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy) IRB 5100331   Children’s Oncology Group   Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years IRB 5110017   Children’s Oncology Group   Children's Oncology Group (COG) - AEWS1031: A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma IRB 5110175   Children’s Oncology Group   COG-AAML1031: A phase III randomized trial for patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for patients with high allelic ratio FLT3/ITD IRB 5110296   Children’s Oncology Group   COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations IRB 5120126   Children’s Oncology Group   COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor IRB 5120321   Reeves, Mark E   TSLP and pediatric leukemia mechanisms and treatment IRB 5130167   Children’s Oncology Group   Pediatric blood and marrow transplant consortium (PBMTC) and Canadian Institutes of Health Research (CIHR) - GVHD-1202: Predictive biomarkers for pediatric chronic graft-versus-host disease IRB 5130381   Children’s Oncology Group   COG - ANHL12P1: A randomized phase 2 trial of Brentuximab Vedotin or Crizotinib in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IRB 5140278   Children’s Oncology Group   COG-ANBL 1232:Utilizing response and biology based risk factors to guide therapy in patients with non-high risk neuroblastoma IRB 5140321   Children’s Oncology Group   COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) IRB 5140416   Children’s Oncology Group   Children's Oncology Group (COG) AALL1331: Risk-stratified randomized phase III testing of blinatumomab (IND#117467, NSC#765986) in first relapse of childhood B-Lymphoblastic Leukemia (B-ALL) IRB 5150002   Children’s Oncology Group   COG AEWS1221: Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab (AMG 479, NSC# 120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma IRB 5150093   Children’s Oncology Group   COG AHOD 1331: randomized phase III study of Brentuximab Vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin Lymphoma (cHL) in children and adolescents IRB 5150354   Children’s Oncology Group   COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid IRB 5160047   Children’s Oncology Group   COG-APEC14B1: project: EveryChild - a registry, eligibility screening, biology and outcome study IRB 5160052   Children’s Oncology Group   COG A031102: a randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus Ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors IRB 5160061   Children’s Oncology Group   COG AAML1531: Risk-stratified therapy for acute myeloid leukemia in Down Syndrome IRB 5160087   Children’s Oncology Group   COG AOST1421: A phase 2 study of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 (Dinutuximab, NSC #764038, IND #4308) in combination with sargramostim (GM-CSF) in patients with recurrent osteosarcoma IRB 5160300   Children’s Oncology Group   COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS) IRB 5160357   Children’s Oncology Group   COG AALL 1521 / Incyte INCB 1824-269: A phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with chemotherapy in children with De Novo high-risk CRLF2-rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia IRB 5170232   Children’s Oncology Group   COG AGCT1531: A phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs. cisplatin for standard risk pediatric and adult patients with germ cell tumors IRB 5170332   Children’s Oncology Group   COG AALL1621: phase 2 study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in children and young adults with relapsed or refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) IRB 5170405   Children’s Oncology Group   COG ACNS1422: A Phase 2 Study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients IRB 5170407   Children’s Oncology Group   COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones IRB 5180038   Children’s Oncology Group   Nationwide Children's Hospital - Head start IV: Newly diagnosed children (less than 10 years old) with Medulloblastoma and other central nervous system embryonal tumors: Clinical and molecular risk-tailored intensive and compressed induction chemotherapy followed by consolidation with randomization to either single-cycle or to three tandem cycles of marrow-ablative chemotherapy with autologous hematopoietic progenitor cell rescue IRB 5180156   Children’s Oncology Group   COG APEC1621: NCI-COG pediatric MATCH (Molecular Analysis for Therapy Choice) IRB 5180370   Children’s Oncology Group   COG ANBL1531: A Phase 3 study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib added to intensive therapy for children with newly diagnosed high-risk neuroblastoma (NBL) (IND# 134379) IRB 5190014   Children’s Oncology Group   EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas IRB 5190140   Children’s Oncology Group   COG AGCT1532: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors IRB 5190151   Children’s Oncology Group   COG AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) IRB 5190263   Children’s Oncology Group   COG AALL1731: A Phase 3 trial investigating Blinatumomab (IND #117467, NSC #765986) in combination with Chemotherapy in patients with newly diagnosed standard risk or down Syndrome B Lymphoblastic Leukemia (B-ALL) and the treatment of patients with localized B-Lymphoblastic Lymphoma (B-LLy) IRB 5190333   Children’s Oncology Group   COG ADVL1822/ Daiichi Sankyo, Inc. AC220-A-U202: A Phase 1/2, Multicenter, Dose-Escalating study to evaluate the safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib administration in combination with re-induction chemotherapy, and as a single-agent continuation therapy, in pediatric relapsed/refractory AML subjects ages 1 month to &lt18 years (and Young adults ages up to 21 years) with FLT3-ITB mutations IRB 5190358   Abdel-azim, Hisham M.   PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative IRB 5190442   Children’s Oncology Group   COG AALL1732: A phase 3 randomized trial of Inotuzumab Ozogamicin for newly diagnosed high-risk B-ALL; Risk adapted post-induction therapy for high-risk B-ALL, mixed Phenotype acute Leukemia, and Disseminated B-LLy IRB 5200180   Children’s Oncology Group   COG ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND #145355) IRB 5200225   Children’s Oncology Group   COG ACNS 1831 : A Phase 3 Randomized Study of Selumetinib versus CarboplatiniVincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NFl) associated Low-Grade Glioma (LGG) IRB 5200330   Children’s Oncology Group   COG ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) IRB 5200343   Children’s Oncology Group   COG AMML 1831: A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FL T3 Inhibitor Gilteritinib for Patients with FL T3 Mutations IRB 5200394   Children’s Oncology Group   COG AAML 1921 / ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia IRB 5210087   Chandnani, Harsha Kailash   Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection: An Institutional Experience IRB 5210122   Kheradpour, Albert   SWOG S1826: A Phase 111, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lvmphoma IRB 5210124   Children’s Oncology Group   COG AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged 1-30 Years with First Relapse         (06/2023 - 12/2023)
  • Funded Grant : American Thrombosis and Hemostasis Network 2022 Data Grant Principal Investigator (12/2021 - 12/2022)
  • PODCAST :  Amplify Sickle Cell Voices International Topic : Sickle Cell Treatment , Investigation & COVID 19 vaccination a Global outlook Podcast In English & Hindi  (04/2022 - Present)
  • Original project’s as Principal Investigator           (01/2021 - Present)